— Know what they know.
Not Investment Advice
Also trades as: DXRX.L (LSE) · $vol 1M

DIUXF OTC

Diaceutics PLC
1W: +15.5% 1M: +15.5% 3M: +15.5% YTD: +68.6% 1Y: +68.6% 3Y: +68.6% 5Y: +53.0%
$2.31
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Healthcare Information Services · Tech Score Buy · Power 72 · $195.2M mcap · 49M float · 0.0067% daily turnover · Short 50% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$195.2M
52W Range1.3672-2.51
Volume3,500
Avg Volume3,285
Beta0.89
Dividend—
Analyst Ratings
1 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEORyan Keeling
Employees205
SectorHealthcare
IndustryMedical - Healthcare Information Services
IPO Date2020-05-29
Building Two
Belfast, AT BT9 6GW
GB
+44 28 9042 8133
About Diaceutics PLC

Diaceutics PLC operates as a global diagnostic commercialization entity, providing pharmaceutical companies worldwide with essential data, sophisticated analytics, and implementation support. Central to its offerings is the DXRX platform, a comprehensive suite designed to address various aspects of precision medicine. This platform delivers: DXRX Data Solutions: Granting access to a vast network of laboratory diagnostic testing data. Key components here include DXRX Signal (for specific data insights), Lab Mapping, a Testing Dashboard, and Physician Mapping services. DXRX Marketplace Solutions: A crucial hub that fosters collaborations between laboratories, pharmaceutical firms, and diagnostic companies to advance precision medicine initiatives. DXRX Patient Journey: Enables pharmaceutical clients to conduct in-depth, longitudinal analyses of individual patient biomarker testing pathways. This insight is vital for pinpointing opportunities for earlier intervention and optimized treatment strategies. DXRX Lab Benchmarking: Empowers laboratories to enhance their competitive standing by comparing critical performance metrics – such as disease profiles, testing methodologies, market share, and turnaround times – against industry peers. DXRX Test Reimbursement: Facilitates pharmaceutical companies' engagement with laboratories to secure funding for the launch of novel companion diagnostics, thereby accelerating test adoption and market penetration. DXRX Test Signal: Provides real-time alerts regarding testing events, enabling pharmaceutical clients to quickly identify patients who may benefit from specific therapies. Beyond the DXRX platform, Diaceutics offers a range of supplementary services. These include strategic consulting for precision medicine diagnostics, as well as diagnostic landscape analysis, planning, implementation, and tracking. The company also provides support for test standardization, quality assessment, report optimization, laboratory technical assistance, test access and reimbursement solutions, comprehensive laboratory training, and educational resources. Established in 2005, Diaceutics PLC maintains its headquarters in Belfast, United Kingdom.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms